



Date: 30 January 2017

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operational Office:

Suite 4 Level 3, Bdg 2
20 Bridge St
Pymble NSW 2073
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

APPENDIX 4C – 31 DECEMBER 2016 QUARTER

Noxopharm Ltd is pleased to release its Appendix 4C for the quarter ended 31 December 2016.

Since the release of the prior quarter results, the Company has:

- developed a strategic drug development plan embracing both clinical and pre-clinical programs;
- provided preliminary details regarding its planned 5 clinical studies scheduled to commence in the first half of 2017;
- announced first-in-human Phase 1 study approved. (Note, protocol amendment requested by Company. Study now expected to commence Feb 2017);
- made 3 key medical appointments as part of the expansion of its clinical team to coincide with the initiation of its NOX66 clinical trials program;
- announced lodgment of a new patent in relation to its NOX66 delivery technology successfully delivering high levels of the experimental anti-cancer drug, idronoxil, across the blood-brain barrier to the brain; and
- in order to streamline its expanding operations, moved its administrative functions from Melbourne to Sydney, including the appointment of a Sydney-based Company Secretary and Financial Officer, Mr David Franks.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. Its purpose is to ensure that most idronoxil administered remains in an active form. Idronoxil works by cancelling pro-survival mechanisms in cancer cells that allow the cells to resist the killing effects of chemotherapies and radiotherapy.

INVESTOR AND MEDIA ENQUIRIES: Prue Kelly
E: info@noxopharm.com T: + 61 2 9144 2223

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

NOXOPHARM LIMITED

ABN

50 608 966 123

Quarter ended ("current quarter")

31 DECEMBER 2016

| Consolidated statement of cash flows | Current quarter \$A'000 | Year to date (6 months) \$A'000 |
|---|------------------------------------|--|
| 1. Cash flows from operating activities | | |
| 1.1 Receipts from customers | | |
| 1.2 Payments for | | |
| (a) research and development | (84) | (251) |
| (b) product manufacturing and operating costs | | |
| (c) advertising and marketing | (37) | (96) |
| (d) leased assets | | |
| (e) staff costs | (205) | (480) |
| (f) administration and corporate costs | (123) | (277) |
| 1.3 Dividends received (see note 3) | | |
| 1.4 Interest received | 25 | 29 |
| 1.5 Interest and other costs of finance paid | - | (1) |
| 1.6 Income taxes paid | | |
| 1.7 Government grants and tax incentives | | |
| 1.8 Other (Listing process costs) | - | (165) |
| 1.9 Net cash from / (used in) operating activities | (424) | (1,241) |
| 2. Cash flows from investing activities | | |
| 2.1 Payments to acquire: | | |
| (a) property, plant and equipment | (6) | (12) |
| (b) businesses (see item 10) | | |
| (c) investments | | |

| Consolidated statement of cash flows | Current quarter \$A'000 | Year to date (6 months) \$A'000 |
|---|------------------------------------|--|
| (d) intellectual property | | |
| (e) other non-current assets | (64) | (64) |
| 2.2 Proceeds from disposal of: | | |
| (a) property, plant and equipment | | |
| (b) businesses (see item 10) | | |
| (c) investments | | |
| (d) intellectual property | | |
| (e) other non-current assets | | |
| 2.3 Cash flows from loans to other entities | | |
| 2.4 Dividends received (see note 3) | | |
| 2.5 Other (provide details if material) | | |
| 2.6 Net cash from / (used in) investing activities | (70) | (76) |

| | | |
|---|------------|----------------|
| 3. Cash flows from financing activities | | |
| 3.1 Proceeds from issues of shares | - | 6,000 |
| 3.2 Proceeds from issue of convertible notes | | |
| 3.3 Proceeds from exercise of share options | | |
| 3.4 Transaction costs related to issues of shares, convertible notes or options | (8) | (512) |
| 3.5 Proceeds from borrowings | | |
| 3.6 Repayment of borrowings | | |
| 3.7 Transaction costs related to loans and borrowings | | |
| 3.8 Dividends paid | | |
| 3.9 Other (provide details if material) | | |
| 3.10 Net cash from / (used in) financing activities | (8) | (5,488) |

| | | |
|---|-------|---------|
| 4. Net increase / (decrease) in cash and cash equivalents for the period | | |
| 4.1 Cash and cash equivalents at beginning of quarter/year to date | 4,834 | 161 |
| 4.2 Net cash from / (used in) operating activities (item 1.9 above) | (424) | (1,241) |
| 4.3 Net cash from / (used in) investing activities (item 2.6 above) | (70) | (76) |
| 4.4 Net cash from / (used in) financing activities (item 3.10 above) | (8) | 5,488 |

| Consolidated statement of cash flows | | Current quarter \$A'000 | Year to date (6 months) \$A'000 |
|---|--|------------------------------------|--|
| 4.5 | Effect of movement in exchange rates on cash held | | |
| 4.6 | Cash and cash equivalents at end of quarter | 4,332 | 4,332 |

| 5. | Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter \$A'000 | Previous quarter \$A'000 |
|------------|---|------------------------------------|-------------------------------------|
| 5.1 | Bank balances | 1,477 | 1,300 |
| 5.2 | Call deposits | 2,800 | 3,500 |
| 5.3 | Bank overdrafts | | |
| 5.4 | Other (provide details) | 55 | 34 |
| 5.5 | Cash and cash equivalents at end of quarter (should equal item 4.6 above) | 4,332 | 4,834 |

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

| Current quarter \$A'000 |
|------------------------------------|
| 138 |
| - |

Director fees and salary for executive director and related parties.

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

| Current quarter \$A'000 |
|------------------------------------|
| - |
| - |

| 8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i> | Total facility amount at quarter end \$A'000 | Amount drawn at quarter end \$A'000 |
|--|--|---|
| 8.1 Loan facilities | - | - |
| 8.2 Credit standby arrangements | - | - |
| 8.3 Other (please specify) | - | - |
| 8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well. | | |

| |
|--|
| |
|--|

| 9. Estimated cash outflows for next quarter | \$A'000 |
|--|--------------|
| 9.1 Research and development | (325) |
| 9.2 Product manufacturing and operating costs | - |
| 9.3 Advertising and marketing | (60) |
| 9.4 Leased assets | - |
| 9.5 Staff costs | (252) |
| 9.6 Administration and corporate costs | (175) |
| 9.7 Other (provide details if material) | |
| - Fitout costs for new premise | (60) |
| 9.8 Total estimated cash outflows | (872) |

| 10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above) | Acquisitions | Disposals |
|--|--------------|-----------|
| 10.1 Name of entity | N/A | N/A |
| 10.2 Place of incorporation or registration | - | - |
| 10.3 Consideration for acquisition or disposal | - | - |
| 10.4 Total net assets | - | - |
| 10.5 Nature of business | N/A | N/A |

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



30 January 2017

Sign here:
(Company secretary)

Date:

Print name:

DAVID FRANKS

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.